DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA613643
Title:
A Combination Therapy of JO-1 and Chemotherapy in Ovarian Cancer Models
Descriptive Note:
Final rept. 30 Sep 2012-29 Sep 2014
Corporate Author:
WASHINGTON UNIV SEATTLE
Report Date:
2014-12-01
Pagination or Media Count:
104.0
Abstract:
- A manufacturing protocol for JO-1 with and without His-tag at large scale has been established. - There were no adverse effects after intravenous injection of JO-1 in DSG2 transgenic mice. - JO-1 has favorable pharmacokinetics parameters. - The effect of JO-1 on normal tissues is minimal because DSG2 is trapped in epithelial junctions in normal tissues and not accessible to intravenously injected JO-1. - JO-1 enhances Doxil chemotherapy in xenograft models of ovarian cancer and in mouse models with syngeneic tumors. - JO-1 continues to be effective after multiple treatment cycles even in the presence of detectable antibodies. - JO-1 facilitates pre-existing anti-tumor T-cell responses. - An affinity-enhanced version of JO-1 called JO-4 was produced. - JO-4 co-therapy allows for reduction of effective Doxil dose in a xenograft model of ovarian cancer. - JO-4 increases the therapeutic effect of Doxil on lymphogenic metastases. - Combined treatment with JO-4 and Doxil is safe in non-human primates
Distribution Statement:
APPROVED FOR PUBLIC RELEASE